Contract Research Organization



	PSI is a leading full-service global Contract Research Organization whose key strength is predictable patient enrollment across multiple therapeutic areas. PSI is known in the industry as a CRO focused on on-time project delivery. This is achieved through investing substantial effort and MD resources into performing quality feasibility assessments that provide an accurate predictor of study timelines.

Full Name

Details

Week 3, 2012

PSI met an interim enrollment milestone of 450 randomized pediatric patients in a phase III study of a novel antiemetic used for the prevention of postoperative nausea and vomiting (PONV).
PSI reached an interim enrollment target of 150 randomized patients in a phase II study of a novel antineoplastic agent in pancreatic cancer.
PSI met an interim enrollment target of 300 randomized patients in a phase III study of a novel biological agent in multiple myeloma.
PSI completed the active treatment period in a phase II study of a novel combination product in patients with asthma.
PSI completed a phase II study of a novel biological agent in patients with renal cell carcinoma.

Vice President, USA, September 2011

"The PSI team provides outstanding service on executing clinical research for sponsor companies. The fees are reasonable, the work exemplary and they always deliver what they promise. I would use PSI again for CRO services anytime."